{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:26:28Z","timestamp":1773332788140,"version":"3.50.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Carcinogenesis and acquisition of multidrug resistance within established cancers are both multistep evolutionary processes in which stem cells play a role. This perspective will briefly review two corresponding theoretical constructs under development. Efficiency of carcinogenesis (EOC) considers multistep carcinogenesis and predicts the effect of differing dynamics on the efficiency of generating a transformed founder cell. EOC has been applied to evaluation of the role of genetic instability in carcinogenesis. Dynamic precision medicine (DPM) is a method for providing personalized treatment sequences for cancer while explicitly considering intracancer subclonal heterogeneity and evolutionary dynamics (growth and evolutionary rates). It adapts therapy frequently and proactively by anticipating the kinetics of multidrug resistance prior to its detection, and prioritizing its prevention. Simulations suggest potential to substantially increase survival and cure rates across a broad range of clinical presentations. Both of these problems implicate very small subclones within stem cell and\/or differentiated compartments, and evolution may occur over months to years. We describe novel experimental technologies for quantifying longitudinal dynamics of very large numbers of cells for prolonged periods, allowing detection and tracking of rare events and their evolution over time. We further highlight two potential applications. In Fanconi anemia, optimal treatment sequences for minimizing bone marrow failure while not increasing the risk of leukemia may be designed using EOC and DPM and tested in laboratory models. In refractory acute myeloid leukemia, high throughput molecular characterization and drug sensitivity screening of subclones is showing clinical promise, and may be further optimized with DPM.<\/jats:p>","DOI":"10.1093\/stcltm\/szag008","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:37:41Z","timestamp":1770122261000},"source":"Crossref","is-referenced-by-count":0,"title":["Towards evolutionary guided precision medicine of acute myeloid leukemia and Fanconi anemia associated bone marrow failure"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-9210","authenticated-orcid":false,"given":"Robert A","family":"Beckman","sequence":"first","affiliation":[{"name":"Departments of Oncology and of Biostatistics, Bioinformatics & Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela S","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation and Department of Hematologic Malignancies Translational Science, City\u00a0of Hope , Duarte, CA 91010,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Gallini","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University , Boston, MA 02215,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary M","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Departments of Oncology, Pediatrics, and Internal Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvin P","family":"Makohon-Moore","sequence":"additional","affiliation":[{"name":"Hackensack Meridian Health Center for Discovery and Innovation , Nutley, NJ 07110,","place":["United States"]},{"name":"Hackensack Meridian School of Medicine , Nutley, NJ 07110,","place":["United States"]},{"name":"Georgetown University Lombardi Comprehensive Cancer Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D","family":"McCoy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr","family":"Sverdlov","sequence":"additional","affiliation":[{"name":"Advanced Quantitative Sciences, Novartis Pharmaceutical Corporation , East Hanover , NJ 07936,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026031200322791800_szag008-B1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"2026031200322791800_szag008-B2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2004.07.009","article-title":"Species and cell type-specific requirements for cellular transformation","volume":"6","author":"Rangarajan","year":"2004","journal-title":"Cancer Cell"},{"key":"2026031200322791800_szag008-B3","doi-asserted-by":"crossref","first-page":"14140","DOI":"10.1073\/pnas.0606271103","article-title":"Efficiency of carcinogenesis with and without a mutator mutation","volume":"103","author":"Beckman","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"2026031200322791800_szag008-B4","doi-asserted-by":"publisher","first-page":"e5860","DOI":"10.1371\/journal.pone.0005860","article-title":"Mutator mutations enhance tumorigenic efficiency across fitness landscapes","volume":"4","author":"Beckman","year":"2009","journal-title":"PLoS One"},{"key":"2026031200322791800_szag008-B5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.semcancer.2010.10.004","article-title":"Efficiency of carcinogenesis: is the mutator phenotype inevitable?","volume":"20","author":"Beckman","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"2026031200322791800_szag008-B6","doi-asserted-by":"crossref","first-page":"14586","DOI":"10.1073\/pnas.1203559109","article-title":"Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer","volume":"109","author":"Beckman","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"2026031200322791800_szag008-B7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/pme.14.57","article-title":"Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes","volume":"11","author":"Beckman","year":"2014","journal-title":"Per Med"},{"key":"2026031200322791800_szag008-B8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13062-016-0153-2","article-title":"Long range personalized cancer treatment strategies incorporating evolutionary dynamics","volume":"11","author":"Yeang","year":"2016","journal-title":"Biol Direct"},{"key":"2026031200322791800_szag008-B9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cpt.1938","article-title":"Rare mutations in cancer drug resistance and implications for therapy","volume":"108","author":"Beckman","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026031200322791800_szag008-B10","doi-asserted-by":"publisher","first-page":"e2300714","DOI":"10.1200\/PO.23.00714","article-title":"A generalized evolution classifier (EC) for evolutionary guided precision medicine (EGPM)","volume":"9","author":"McCoy","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026031200322791800_szag008-B11","first-page":"2311","article-title":"Errors in DNA replication as a basis of malignant changes","volume":"34","author":"Loeb","year":"1974","journal-title":"Cancer Res"},{"key":"2026031200322791800_szag008-B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2217\/ijh-2017-0002","article-title":"Understanding the molecular basis of acute myeloid leukemias: where are we now?","volume":"6","author":"Gruzka","year":"2017","journal-title":"Int J Hematol Oncol"},{"key":"2026031200322791800_szag008-B13","doi-asserted-by":"publisher","first-page":"101137","DOI":"10.1016\/j.neo.2025.101137","article-title":"STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes","volume":"61","author":"King","year":"2025","journal-title":"Neoplasia"},{"key":"2026031200322791800_szag008-B14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2014-04-522136","article-title":"Recent developments in myelodysplastic syndromes","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"2026031200322791800_szag008-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1954.1","article-title":"The age distribution of cancer and a multi-stage theory of carcinogenesis","volume":"8","author":"Armitage","year":"1954","journal-title":"Br J Cancer"},{"key":"2026031200322791800_szag008-B16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ijc.2910040113","article-title":"A mathematical model or the age distribution of cancer in man","volume":"4","author":"Cook","year":"1969","journal-title":"Int J Cancer"},{"key":"2026031200322791800_szag008-B17","doi-asserted-by":"crossref","first-page":"15095","DOI":"10.1073\/pnas.222118199","article-title":"Multistage carcinogenesis and the incidence of colorectal cancer","volume":"99","author":"Luebeck","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"2026031200322791800_szag008-B18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.semcancer.2005.06.007","article-title":"Genetic instability in cancer: theory and experiment","volume":"15","author":"Beckman","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"2026031200322791800_szag008-B19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"2026031200322791800_szag008-B20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"2026031200322791800_szag008-B21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0165-4608(86)90378-X","article-title":"Karyotypic evolution in human malignant melanoma","volume":"19","author":"Balaban","year":"1986","journal-title":"Cancer Genet Cytogenet"},{"key":"2026031200322791800_szag008-B22","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1534\/genetics.105.040840","article-title":"Negative clonal selection in tumor evolution","volume":"171","author":"Beckman","year":"2005","journal-title":"Genetics"},{"key":"2026031200322791800_szag008-B23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1534\/genetics.113.160960","article-title":"DNA replication error-induced extinction of diploid yeast","volume":"196","author":"Herr","year":"2014","journal-title":"Genetics"},{"key":"2026031200322791800_szag008-B24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"2026031200322791800_szag008-B25","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood-2014-04-526293","article-title":"Stress and DNA repair biology of the Fanconi anemia pathway","volume":"124","author":"Longerich","year":"2014","journal-title":"Blood"},{"key":"2026031200322791800_szag008-B26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-cancerbio-030617-050422","article-title":"The Fanconi anemia pathway in cancer","volume":"3","author":"Niraj","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"key":"2026031200322791800_szag008-B27","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41388-023-02800-9","article-title":"FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations","volume":"42","author":"Pawlikowska","year":"2023","journal-title":"Oncogene"},{"key":"2026031200322791800_szag008-B28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.dnarep.2010.05.006","article-title":"Reply: is there any genetic instability in human cancer?","volume":"9","author":"Fox","year":"2010","journal-title":"DNA Repair (Amst)"},{"key":"2026031200322791800_szag008-B29","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026031200322791800_szag008-B30","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by duplex sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"},{"key":"2026031200322791800_szag008-B31","doi-asserted-by":"crossref","first-page":"26863","DOI":"10.1073\/pnas.1910301116","article-title":"Extensive subclonal mutational diversity in human colorectal cancer and its significance","volume":"116","author":"Loeb","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026031200322791800_szag008-B32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41540-024-00436-3","article-title":"Neutral evolution of rare cancer mutations in the computer and the clinic","volume":"10","author":"Beckman","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"2026031200322791800_szag008-B33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature10733","article-title":"A novel retinoblastoma therapy from genomic and epigenetic analyses","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"2026031200322791800_szag008-B34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/eva.12024","article-title":"Modelling the evolution of genetic instability during tumor progression","volume":"6","author":"Datta","year":"2013","journal-title":"Evol Appl"},{"key":"2026031200322791800_szag008-B35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.dnarep.2017.06.002","article-title":"Evolutionary dynamics and significance of multiple subclonal mutations in cancer","volume":"56","author":"Beckman","year":"2017","journal-title":"DNA Repair (Amst)"},{"key":"2026031200322791800_szag008-B36","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195079517.001.0001","volume-title":"The Origins of Order","author":"Kauffman","year":"1993"},{"key":"2026031200322791800_szag008-B37","doi-asserted-by":"publisher","first-page":"1007784","DOI":"10.3389\/fdgth.2022.1007784","article-title":"Exploring approaches for predictive cancer digital twins: opportunities for collaboration and innovation","volume":"4","author":"Stahlberg","year":"2022","journal-title":"Front Digit Health"},{"key":"2026031200322791800_szag008-B38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aat7171","article-title":"Minimal functional driver gene heterogeneity among untreated metastases","volume":"361","author":"Reiter","year":"2018","journal-title":"Science"},{"key":"2026031200322791800_szag008-B39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nm.3841","article-title":"Studying clonal dynamics in response to cancer therapy with high-complexity barcoding","volume":"21","author":"Bhang","year":"2015","journal-title":"Nat Med"},{"key":"2026031200322791800_szag008-B40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc.2016.66","article-title":"Pancreatic cancer and biology from an evolutionary perspective","volume":"16","author":"Makohon-Moore","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026031200322791800_szag008-B41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.trecan.2024.06.011","article-title":"Emerging and extensive evolution in the pancreas","volume":"10","author":"Makohon-Moore","year":"2024","journal-title":"Trends Cancer"},{"key":"2026031200322791800_szag008-B42","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41375-023-01945-6","article-title":"RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia","volume":"37","author":"Marion","year":"2023","journal-title":"Leukemia"},{"key":"2026031200322791800_szag008-B43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","article-title":"The influence of subclonal resistance mutations on targeted cancer therapy","volume":"13","author":"Schmitt","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2026031200322791800_szag008-B44","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/leu.2012.217","article-title":"The proportion of CD34+CD38low or neg myeloblasts, but not side population (SP) frequency, predicts initial response to induction chemotherapy in patients with newly diagnosed acute myeloid leukemia","volume":"27","author":"Roshal","year":"2013","journal-title":"Leukemia"},{"key":"2026031200322791800_szag008-B45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2018-180","article-title":"High throughput drug screening of leukemia stem cells reveals resistance to standard therapies and sensitivity to other agents in acute myeloid leukemia","volume":"132","author":"Mabrey","year":"2018","journal-title":"Blood"},{"key":"2026031200322791800_szag008-B46","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1182\/blood.2024027270","article-title":"Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome","volume":"145","author":"Chen","year":"2025","journal-title":"Blood"},{"key":"2026031200322791800_szag008-B47","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1158\/1078-0432.CCR-23-1674","article-title":"Mutation patterns predict drug sensitivity in acute myeloid leukemia","volume":"30","author":"Qin","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026031200322791800_szag008-B48","doi-asserted-by":"crossref","first-page":"106822","DOI":"10.1016\/j.leukres.2022.106822","article-title":"Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation duplex sequencing","volume":"115","author":"Kamath-Loeb","year":"2022","journal-title":"Leuk Res"},{"key":"2026031200322791800_szag008-B49","doi-asserted-by":"publisher","author":"Parashar","year":"2025","DOI":"10.1101\/2025.05.23.25328210"},{"key":"2026031200322791800_szag008-B50","doi-asserted-by":"publisher","author":"He","year":"2025","DOI":"10.1101\/2025.10.10.681641"},{"key":"2026031200322791800_szag008-B51","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"key":"2026031200322791800_szag008-B52","doi-asserted-by":"publisher","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Chmielecki","year":"2011","journal-title":"Sci Transl Med"},{"key":"2026031200322791800_szag008-B53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2013.12.029","article-title":"Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules","volume":"156","author":"Leder","year":"2014","journal-title":"Cell"},{"key":"2026031200322791800_szag008-B54","doi-asserted-by":"crossref","first-page":"1073274820962008","DOI":"10.1177\/1073274820962008","article-title":"How should cancer models be constructed?","volume":"27","author":"Beckman","year":"2020","journal-title":"Cancer Control"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/3\/szag008\/67306433\/szag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/3\/szag008\/67306433\/szag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:32:43Z","timestamp":1773289963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szag008\/8515056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,25]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szag008","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,25]]},"article-number":"szag008"}}